Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irish biopharmaceutical firm Shire has entered into an agreement with Sanquin Blood Supply for Cinryze (C1 esterase inhibitor [human]), which is used for the prophylactic treatment of hereditary angioedema (HAE).
Subscribe to our email newsletter
The deal provides Shire with access to Sanquin’s manufacturing technology and allowing the Irish firm to source additional manufacturers to meet the growing demand for Cinryze.
Shire CEO Flemming Ornskov said: "We wanted the freedom to operate and expand in a way that makes strategic sense for our business.
"When Shire acquired ViroPharma in January 2014, we inherited an arrangement under which Sanquin was the exclusive manufacturer for Cinryze.
"We’re pleased that Sanquin was open to expanding our partnership and agreeing to support us as we increase production options for this important therapy."
The agreement involves payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer.
The deal will see Sanquin continue to serve as a key partner with Shire to increase global supply of Cinryze.
HAE is a rare genetic disease characterized by recurrent sudden attacks of swelling of the skin or the mucous membranes which can be disfiguring, painful and potentially life-threatening in the case of laryngeal attacks.